Pharma companies still slow to adopt hybrid sales rep and digital commercial models – survey
After the pandemic spurred a rush to digital commercialization strategies, pharma companies realized they needed to evolve their traditional sales rep-led models. However, they’re still unsure about how best to do that, according to a new survey of pharma leaders.
One key uncertainty is around exactly what a hybrid commercial model is. One-fourth of respondents said a hybrid commercial model is sales reps using their own digital strategies, while another 23% said it’s sales reps using corporate-driven digital channels, according to Indegene’s survey of 100 marketing, sales and commercial leaders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
